• Moving into a career in Pharmacovigilance

    The Drug Safety Research Unit (DSRU) offers a range of Pharmacovigilance (PV) training courses suitable for those looking for a career in pharmacovigilance, seeking career progression or in a position that requires PV knowledge and understanding. Depending on specific interests and current knowledge, the team at the DSRU is able to recommend which of our training courses could help […]

    >Continue reading
  • Regulations in the EU and globally: Spotlight on 2 courses

    The DSRU provide a range of training courses covering numerous topics within Pharmacovigilance (PV). One topic that is featured in many courses, due to its importance and relevance to all aspects of PV, is regulations. Two of our courses focus on regulations, one from an EU perspective, EU Regulations and Guidelines, and one from a Global […]

    >Continue reading
  • How can I attend the DSRU courses?

    The DSRU has been providing pharmacovigilance training courses in the UK since 2000, to fulfil the requirements of professionals from around the world in pharmacovigilance. We are one of the leading providers of pharmacovigilance training courses and education in Europe, providing high academic standards at low costs. All of the short courses offered by the […]

    >Continue reading
  • Are any of your courses suitable if I am new to Pharmacovigilance?

    The DSRU offers a range of Pharmacovigilance (PV) training courses suitable for those new to the industry, seeking career progression or in a position that requires PV knowledge and understanding. We have selected 2 of our PV training courses that would be suitable for someone new to PV or working in a support role: Back to Basics in […]

    >Continue reading
  • Why are post-marketing studies important?

    Post-marketing studies, often referred to as post-marketing surveillance, are an integral part of promoting and ensuring safety, particularly in safeguarding patients from any unwanted adverse effects associated with medicines that are new to the market. Prior to the launch and use of any new drug, the marketing authorisation holder must submit a Risk Management Plan […]

    >Continue reading